Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers-Reference-Cited by-同舟云学术

Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers

Published:2011-11-01 Issue:11 Volume:121 Page:4311-4321
ISSN:0021-9738
Container-title:Journal of Clinical Investigation
language:en
Short-container-title:J. Clin. Invest.

Author:

Ebi Hiromichi,Corcoran Ryan B.,Singh Anurag,Chen Zhao,Song Youngchul,Lifshits Eugene,Ryan David P.,Meyerhardt Jeffrey A.,Benes Cyril,Settleman Jeffrey,Wong Kwok-Kin,Cantley Lewis C.,Engelman Jeffrey A.

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Reference55 articles.

1. Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

2. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

3. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

4. Factors underlying sensitivity of cancers to small-molecule kinase inhibitors

5. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer

Cited by 179 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The combination of SHP099 inhibits the malignant biological behavior of L-OHP/5-FU-resistant colorectal cancer cells by regulating energy metabolism reprogramming;Biochemical and Biophysical Research Communications;2024-10

2. Towards Targeting Endothelial Rap1B to Overcome Vascular Immunosuppression in Cancer;International Journal of Molecular Sciences;2024-09-12

3. Tyrosine kinases: multifaceted receptors at the intersection of several neurodegenerative disease-associated processes;Frontiers in Dementia;2024-08-16

4. A first-in-class selective inhibitor of EGFR and PI3K offers a single-molecule approach to targeting adaptive resistance;Nature Cancer;2024-07-11

5. Drug Combination Therapy for RAS-related Colorectal Cancer;PROG BIOCHEM BIOPHYS;2023